Motpoly XR Shortage: What Providers and Prescribers Need to Know in 2026

As prescribers, you are on the front lines when patients cannot access their medications. Motpoly XR (lacosamide extended-release) presents a unique set of access challenges that differ from a traditional drug shortage. This guide provides clinical context and practical strategies to help your epilepsy patients maintain uninterrupted treatment in 2026.

Current Availability Status as of 2026

Motpoly XR does not appear on the FDA's current Drug Shortage Database. Aucta Pharmaceuticals has not reported a manufacturing or supply disruption. However, clinicians are increasingly encountering patients who cannot readily fill their prescriptions. The primary barriers are:

Limited pharmacy stocking: Many retail pharmacies do not maintain routine stock of Motpoly XR due to its novelty and limited patient base at individual locations.

Insurance formulary placement: As a brand-name Schedule V medication without a generic equivalent, Motpoly XR is typically placed on Tier 3 or Tier 4 formulary tiers, with prior authorization requirements common across commercial, Medicare Part D, and Medicaid plans.

Step therapy requirements: Some payers require patients to first trial generic lacosamide IR or other lower-tier AEDs before authorizing Motpoly XR.

Clinical Context: Who Benefits Most from Motpoly XR?

Motpoly XR's primary clinical advantage over generic lacosamide IR is once-daily dosing. This is clinically meaningful for:

Patients with poor adherence to twice-daily regimens

Patients managing complex polytherapy where pill burden is a concern

Patients who experienced peak-dose CNS adverse effects (dizziness, diplopia) with twice-daily lacosamide IR, as the extended-release formulation attenuates peak plasma concentrations

Pediatric patients ≥50 kg who struggle with twice-daily dosing schedules at school or during extracurricular activities

Bridging Strategy: Converting to Lacosamide IR

When Motpoly XR is temporarily unavailable, the most clinically appropriate bridge is generic lacosamide immediate-release tablets. Key considerations:

Dose equivalence: The total daily dose of lacosamide remains the same; divide into two equal doses given approximately 12 hours apart.

Bioequivalence at steady state: Steady-state pharmacokinetic data demonstrates bioequivalence between Motpoly XR and lacosamide IR, supporting this conversion.

Monitor for tolerability: Patients who switched to XR specifically due to peak-dose CNS side effects may experience a brief return of those symptoms during the bridge period.

No tapering required: A direct conversion (same total daily dose, split into two doses) is clinically appropriate — no titration period is needed when converting between formulations of the same drug at equivalent doses.

Navigating Prior Authorization for Motpoly XR

Prior authorization is the most common coverage barrier for Motpoly XR. To improve approval rates, your PA documentation should address:

Clinical rationale for once-daily formulation (adherence history, CNS side effect profile with IR, patient-specific factors)

Documentation of prior lacosamide IR trial if required by the payer's step therapy protocol

Seizure frequency and control data to establish medical necessity

Patient-specific safety considerations (e.g., cardiac history, which may influence AED selection)

38,224+ patients found their medications in stock

38K+

Find Motpoly XR In Stock Today →

Patient Financial Assistance Programs

Two programs are available to help patients afford Motpoly XR:

Motpoly XR Copay Savings Card: Eligible commercially insured patients may pay as little as $10 for a 30-day supply. Enrollment typically takes minutes and can be done at the pharmacy counter or online. Contact Aucta Pharmaceuticals at 1-800-655-9902 for details.

Patient Assistance Program (PAP): For uninsured or underinsured patients who meet income criteria, Aucta Pharmaceuticals may provide Motpoly XR at no cost or reduced cost. Contact the manufacturer directly for eligibility requirements.

How medfinder Helps Your Patients

When patients struggle to locate Motpoly XR at their pharmacy, medfinder for providers is a resource worth recommending. medfinder calls pharmacies in the patient's area to check real-time stock of a specific medication, strength, and quantity — then texts the patient a list of pharmacies that can fill the prescription. This eliminates hours of patient phone calls and the anxiety that comes with uncertain access to seizure medication.

For a complete provider-focused approach, see: How to Help Your Patients Find Motpoly XR in Stock.

Skip the calls, skip the stress.

Find Motpoly XR In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Key Takeaways for Prescribers

Motpoly XR is not in an FDA-declared shortage — but real-world access barriers exist due to limited pharmacy stocking, brand-only status, and insurance requirements

Generic lacosamide IR is a clinically appropriate bridge: same total daily dose split into two equal doses 12 hours apart

Provide PA documentation emphasizing once-daily formulation rationale and seizure control history

Direct eligible patients to the Aucta copay card program for immediate cost relief

Recommend medfinder to patients who are struggling to locate Motpoly XR at their pharmacy